Business
Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings
NEWTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"NEWTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 International Myeloma Society (IMS) Annual Meeting, being held September 27-30 in Athens, Greece. In addition, exploratory subgroup analyses from the SIENDO Study in patients with advanced or recurrent TP53 wild-type endometrial cancer will be presented in an oral session, \"Abstract Session: Best Oral Session – Endometrial Cancer,\" at the 2023 European Society of Gynaecological Oncology (ESGO) Congress, being held September 28-October 1 in Istanbul, Turkey.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have a number of presentations at IMS and ESGO this year that continue to show the meaningful benefit achieved with selinexor across a number of tumor types,\" said Reshma Rangwala, MD, PhD, Chief Medical Officer of Karyopharm. \"The breadth of data to be presented further demonstrates our commitment, as well as that of our collaborators, to develop first-in-class therapies that inhibit XPO1 with the goal to improve outcomes for patients across solid and hematological tumors.\"\nDetails for the Karyopharm presentations at ESGO are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nEndometrial Cancer\nLong-term Follow up of Selinexor Maintenance for Patients with TP53wt Advanced or Recurrent Endometrial Cancer: A Pre-Specified Subgroup Analysis from the Phase 3 ENGO-EN5/GOG-3055/SIENDO Study\nOral\n264\nSunday, October 1, 2023\n \n12:05pm – 12:15 pm GMT/ 5:05am -5:15am EST\nENGOT-EN20/GOG-3083/XPORT-EC-042 a Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy for Patients with TP53wt, Advanced or Recurrent Endometrial Carcinoma\nPoster\n265\nSaturday, September 30, 2023\n \n15:05-15:50pm GMT/11:05am – 11:50am \nDetails for the Karyopharm IMS posters are as follows:\nAbstract Title\nPresentation Type\nAbstract #\nSession Date/Time\nMultiple Myeloma\nA Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone Versus Elotuzumab, Pomalidomide, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma \nPoster\nP-323\nThursday, Sept...